Source: European journal of haematology [Eur J Haematol] 2007 Jun; Vol. 78 (6), pp. 540-2. Date of Electronic Publication: 2007 Mar 28.Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0902-4441

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade ®, ICL670).

Authors : Di Tucci, Anna Angela¹; Murru, Roberta¹; Alberti, Daniele²

Subjects: *ANEMIA; *MULTIPLE organ failure; *CHELATION therapy

Source: European Journal of Haematology. Jun2007, Vol. 78 Issue 6, p540-542. 3p. 1 Chart.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study.

Authors : Porter J; University College London, London, UK. ; Galanello R

Subjects: Anemia, Diamond-Blackfan/Anemia, Diamond-Blackfan/Anemia, Diamond-Blackfan/*drug therapy ; Benzoates/Benzoates/Benzoates/*therapeutic use ; Iron Chelating Agents/Iron Chelating Agents/Iron Chelating Agents/*therapeutic use

Source: European journal of haematology [Eur J Haematol] 2008 Feb; Vol. 80 (2), pp. 168-76. Date of Electronic Publication: 2007 Nov 17.Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia

Authors : Shahina Daar; Dany Habr; Hanspeter Nick

Subjects: Adult; Male; medicine.medical_specialty

Source: European Journal of Haematology

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.

Authors : Daar S; Department of Hematology, College of Medicine, Sultan Qaboos University, Muscat, Oman. ; Pathare A

Subjects: Benzoates/Benzoates/Benzoates/*administration & dosage ; Iron/Iron/Iron/*blood ; Iron Chelating Agents/Iron Chelating Agents/Iron Chelating Agents/*administration & dosage

Source: European journal of haematology [Eur J Haematol] 2009 Jun; Vol. 82 (6), pp. 454-7. Date of Electronic Publication: 2008 Dec 22.Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.

Authors : Taher A; Department of Internal Medicine, Hematology, Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon. ; El-Beshlawy A

Subjects: Benzoates/Benzoates/Benzoates/*administration & dosage ; Iron Chelating Agents/Iron Chelating Agents/Iron Chelating Agents/*administration & dosage ; Iron Overload/Iron Overload/Iron Overload/*drug therapy

Source: European journal of haematology [Eur J Haematol] 2009 Jun; Vol. 82 (6), pp. 458-65. Date of Electronic Publication: 2009 Jan 28.Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia.

Authors : Daar, Shahina; Pathare, Anil; Nick, Hanspeter

Subjects: HEMOLYTIC anemia; BLOOD plasma; CARRIER proteins

Source: European Journal of Haematology; Jun2009, Vol. 82 Issue 6, p454-457, 4p, 3 Graphs

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study

Authors : Amal El-Beshlawy; Ulrike Kriemler-Krahn; Ali T. Taher

Subjects: Adult; Male; medicine.medical_specialty

Source: European Journal of Haematology

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study.

Authors : Taher, Ali; El-Beshlawy, Amal; Elalfy, Mohsen S.

Subjects: CARRIER proteins; SERUM; BLOOD plasma

Source: European Journal of Haematology; Jun2009, Vol. 82 Issue 6, p458-465, 8p, 2 Charts, 3 Graphs

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit

Authors : Vassilios, Ladis; Giorgos, Chouliaras; Vasilios, Berdoukas

Subjects: Adult; Male; cardiac disease

Source: European Journal of Haematology

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).

Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade ®, ICL670).

Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study.

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia.

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study.

Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit

اتصل بنا

اتبع